Compare Alliant Energy Corporation (LNT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Summit Therapeutics Inc — how do they compare? Alliant Energy Corporation trades at $70.15 (market cap $17.78B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Alliant Energy Corporation is the larger of the two by market cap, and Alliant Energy Corporation pays a 3.12% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LNT | SMMT | |
|---|---|---|
Market Cap | $17.78B | $12.06B |
Sector | Utilities | Health |
52-Week High | $78.03 | $26.98 |
52-Week Low | $63.62 | $12.55 |
Enterprise Value | $29.88B | $11.39B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $70.25, up 2.98% today, with a bearish technical signal but strong fundamentals including a P/E of 21.7 and net income margin of 18.45%. Recent Q2 2026 earnings of $0.65 per share missed some estimates but beat others, with revenue growth supported by data center demand. The stock is near support at $68, with analyst consensus bullish and a $77.67 price target.
Outlook is positive due to consistent earnings beats, dividend yield, and institutional interest, but risks include high debt levels and competitive pressures. Investors may find value in its stable cash flow and growth in utility demand, though technical weakness suggests cautious entry near support levels.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
